Exploring CAR-macrophages in non-tumor diseases: Therapeutic potential beyond cancer

Journal of Advanced Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

After significant advancements in tumor treatment, personalized cell therapy based on chimeric antigen receptors (CAR) holds promise for transforming the management of various diseases. CAR-T therapy, first approved CAR product, has demonstrated therapeutic potential treating infectious diseases, autoimmune disorders, and fibrosis. CAR-macrophages (CAR-Ms) are emerging as a promising approach immune particularly solid highlighting feasibility using macrophages to eliminate pathogens abnormal cells.

Language: Английский

---

Predictive value of serum cytokines in patients with non-small-cell lung cancer receiving anti-PD-1 blockade therapy: a meta-analysis

Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 16, 2025

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. Immunotherapy, particularly PD-1 inhibitors, has revolutionized the treatment landscape for NSCLC. However, predictive biomarkers inhibitor therapy are still limited. Serum cytokines have emerged as potential predicting outcomes. This meta-analysis aims to investigate value serum in We conducted comprehensive literature search major databases, including PubMed, Google scholar, Embase, and Cochrane database, with focus on published up until October 22, 2024. Studies investigating association between cytokine levels outcomes NSCLC patients receiving were included. The primary progression-free survival (PFS) overall (OS). revealed that elevated IL-6 significantly associated poorer PFS (HR = 2.30, 95% CI [1.39–3.80], P 0.001). Additionally, high IL-10 expression was related after 2.45, [1.26–4.76], 0.009). In contrast, no significant associations found OS various cytokines, IL-4, IL-5, IL-6, IL-8, IL-10, IFN-γ, IL-1β, TNF-α, IL-12p70. demonstrates therapy. These findings suggest may serve Further studies needed validate these results explore underlying mechanisms.

Language: Английский

---

Accuracy of artificial intelligence in detecting tumor bone metastases: a systematic review and meta-analysis

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 18, 2025

Bone metastases (BM) represent a prevalent complication of tumors. Early and accurate diagnosis, however, is significant hurdle for radiologists. Recently, artificial intelligence (AI) has emerged as valuable tool to assist radiologists in the detection BM. This meta-analysis was undertaken evaluate AI diagnostic accuracy Two reviewers performed an exhaustive search several databases, including Wei Pu (VIP) database, China National Knowledge Infrastructure (CNKI), Web Science, Cochrane Library, Ovid-Embase, Ovid-Medline, Wan Fang Biology Medicine (CBM), from their inception December 2024. focused on studies that developed and/or validated techniques detecting BM magnetic resonance imaging (MRI) or computed tomography (CT). A hierarchical model used calculate odds ratio (DOR), negative likelihood (NLR), positive (PLR), area under curve (AUC), specificity (SP), pooled sensitivity (SE). The risk bias applicability were assessed using Prediction Model Risk Bias Assessment Tool (PROBAST), while Transparent Reporting multivariable prediction individual prognosis diagnosis-artificial (TRIPOD-AI) employed evaluating quality evidence. review covered 20 articles, among them, 16 included meta-analysis. results revealed SE 0.88 (0.82–0.92), SP 0.89 (0.84–0.93), AUC 0.95 (0.92–0.96), PLR 8.1 (5.57–11.80), NLR 0.14 (0.09–0.21) DOR 58 (31–109). When focusing algorithms. Based ML, (0.77–0.92), 0.93 (0.91–0.95). DL, (0.81–0.95), (0.81–0.94), (0.93–0.97). underscores substantial value identifying Nevertheless, in-depth large-scale prospective research should be carried out confirming AI's clinical utility management.

Language: Английский

---

A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 9, 2025

Pembrolizumab plus Lenvatinib is regarded as a significant treatment option for advanced unresectable hepatocellular carcinoma (HCC). This study aims to meticulously monitor and identify adverse events (AEs) related this combined therapy, enhance patient safety, offer evidence-based recommendations the appropriate use of these drugs. We gathered drug reactions (ADRs)-related data from FAERS database HCC patients who received Pembrolizumab, both alone in combination with first quarter 2014 fourth 2023. ADRs signal detection was performed using ROR, PRR, BCPNN, MHRA, MGPS methods. on 459 358 AEs treated pembrolizumab lenvatinib, respectively. Using four quantification techniques, we identified 50 38 distinct AEs, which were classified into 15 different System organ class (SOC) categories. Notably, most common associated gastrointestinal disorders hepatobiliary disorders. In groups, frequently reported hepatic encephalopathy, blood bilirubin increased diarrhea. also observed some unexpected such dehydration, skin ulcers, intestinal perforation. The countries reporting highest number United States, followed by China, France, Japan. median onset time its lenvatinib 80.5 days (interquartile range 20.0–217.3 days) 77.5 19.7–212.3 days), offers new insights monitoring management receiving or lenvatinib. It crucial closely safety regimen avoid serious AEs.

Language: Английский

---

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis

BMC Women s Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 7, 2025

This study aimed to evaluate the efficacy and safety of docetaxel plus capecitabine (TX) epirubicin (TE) in treatment human epidermal growth factor 2 (HER2)-negative breast cancer. Relevant studies assessing TX versus TE were systematically searched from PubMed, Cochrane Library, Embase, Web Science databases until February 6, 2025. Progression-free survival (PFS), clinical response, including overall response rate (ORR), disease control (DCR), grade 3/4 adverse events compared. Four articles with moderate methodological quality included. The pooled results revealed no significant differences PFS (hazard ratio [HR] (95% confidence interval CI) = 0.86 (0.70, 1.05), P 0.14), ORR (risk [RR] (95%CI) 1.02 (0.92, 1.14), 0.71), or DCR (RR 0.71) between groups. For events, only combined for neutropenia (95%CI), 0.71 (0.52, 0.95); 0.02) hand-foot syndrome 14.36 (3.45, 59.84); 0.0003) demonstrated two No observed other febrile neutropenia, anemia, thrombocytopenia, nail/hair toxicity, hepatic diarrhea, nausea, vomiting, infection, asthenia, neuropathy. In patients HER2-negative cancer, have comparable benefits efficacy. However, exhibits a reduced incidence but higher likelihood than that TE.

Language: Английский

---

Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11091 - 11091

Published: Oct. 15, 2024

Immune checkpoint inhibitors (ICIs), such as durvalumab, tremelimumab, and atezolizumab, have emerged a significant therapeutic option for the treatment of hepatocellular carcinoma (HCC). In fact, efficacy ICIs single agents or part combination therapies has been demonstrated in practice-changing phase III clinical trials. However, confront several difficulties, including lack predictive biomarkers, primary secondary drug resistance, treatment-related side effects. Herein, we provide an overview current issues future challenges this setting.

Language: Английский

---

The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer

Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(2)

Published: Jan. 3, 2025

Abstract In our previous phase II T1219 trial for advanced biliary tract cancer (ABTC), the combination of nivolumab with modified gemcitabine and S-1 exhibited promising efficacy, while programmed-death-ligand-1 (PD-L1) expression did not predict chemoimmunotherapy efficacy. Lymphocyte-activation-gene-3 (LAG-3), a negative immune checkpoint, is frequently co-expressed PD-L1. This study assessed predictive value LAG-3 in ABTC patients who received chemoimmunotherapy. We analyzed 44 formalin-fixed samples using immunohistochemical staining PD-L1 correlated them clinical efficacy Digital spatial profiling was conducted selected regions interest to examine cell infiltration checkpoint six cases. Three public BTC datasets were used analysis: TCGA-CHOL, GSE32225, GSE132305. positivity observed 38.6% significantly ( P < 0.001). The objective response rate (ORR) higher LAG-3-positive tumors than LAG-3-negative (70.6% vs. 33.3%, = 0.029). level associated an increased ORR (33%, 58%, 100% 1%, 1–9%, ≥ 10%, respectively; 0.018) deeper therapeutic (20.1%, 38.6%, 57.6% same respective groups; 0.04). positively numerous checkpoints. Enrichment CD8 + T cells BTC, indicating that may serve as biomarker identifying immune-inflamed predicting ABTC.

Language: Английский

---

Chimeric antigen receptor-T cells targeting AFP-GPC3 mediate increased antitumor efficacy in hepatocellular carcinoma

Arab Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 31, 2025

Immune checkpoint inhibitors (ICIs) have significantly changed cancer therapy, improving patient survival rates and clinical outcomes. Nevertheless, the use of PD-1/PD-L1 can result in immune-related adverse events (irAEs). This study aims to investigate prevalence associated risk factors irAEs a real-world setting, as well assess their effects on optimal therapeutic A retrospective analysis involved 2523 patients with who received inpatient treatment between January 2018 December 2022. We documented patients' demographic characteristics, PD-1 or PD-L1 inhibitors, modalities, incidences, timing, severity irAEs, efficacy outcomes by reviewing records. Patients were categorized into an group non-irAEs group, former further subdivided multiple single irAE group. Chi-square tests employed evaluate differences baseline characteristics groups, groups. Additionally, logistic regression was utilized identify linked irAEs. Among eligible patients, 1096 reported 1802 incidence 43.4%. individuals, 92.1% classified grade 1-2, while 7.9% 3 higher. IrAEs affected various organ systems, endocrine toxicity (17.7%), hepatic (17.2%), hematologic (11.4%) being most common. 20.5% experienced multi-system The average time for develop within four cycles. Significant gender, age, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), comorbidities, modalities observed but not Compared exhibited higher objective response rate (ORR) disease control (DCR), also showed ORR than indicated that occurrence is related ECOG PS, modalities. may be better benefits.

Language: Английский

---

Risk of Ophthalmotoxicity Associated with Antibody-Drug Conjugates: A Systematic Review and Meta-analysis

Clinical Drug Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: May 14, 2025

Language: Английский

---